Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.
| Revenue (Most Recent Fiscal Year) | $49.22M |
| Net Income (Most Recent Fiscal Year) | $-36.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -71.84% |
| Net Margin (Trailing 12 Months) | -100.69% |
| Return on Equity (Trailing 12 Months) | -68.05% |
| Return on Assets (Trailing 12 Months) | -21.53% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.38 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.38 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.58 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | -- |
| Free Float | -- |
| Market Capitalization | $224.56M |
| Average Volume (Last 20 Days) | 0.17M |
| Beta (Past 60 Months) | 3.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.41% |
| Percentage Held By Institutions (Latest 13F Reports) | 63.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |